Principia
Aug 18, 2020
Sanofi acquires Principia; FDA’s Nod to Roche’s Enspryng; BMS, Dragonfly’s Licensing Deal
New strategy, new outlook: Sanofi takes another step, gains full control over the Principia’s MS treatment Sanofi has inked a definitive agreement with Principia Biopharma to acquire the company, all of its outstanding shares, and its BTK inhibitors in a deal worth USD 3.68 Billion. The deal is expected t...
Read More...
Aug 23, 2018
AZ dragout Entasis; Sierra remunerates Gilead; Principia raises; Harbour BioMed and Kelun pen deal
AstraZeneca dragout Entasis files to fund antibiotic phase 3 for USD 86 Million IPO Massachusetts-based Entasis Therapeutics has spun out to raise up to USD 86 Million through an IPO. The AstraZeneca spinout is attempting to fund a phase 3 trial of a drug to overcome bacterial resistance to beta-lactams. In 2015, ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
